Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 1;18(4):433-434.
doi: 10.2215/CJN.0000000000000130.

Safety of Alkalinization in CKD

Michal L Melamed  1 , Kalani L Raphael  2
Affiliations
Comment

Safety of Alkalinization in CKD

Michal L Melamed et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Raphael KL. Metabolic acidosis and subclinical metabolic acidosis in CKD. J Am Soc Nephrol. 2018 10;29(2):376–382. doi:10.1681/ASN.2017040422 - DOI - PMC - PubMed
    1. Di Iorio BR, Bellasi A, Raphael KL, et al. . Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32(6):989–1001. doi:10.1007/s40620-019-00656-5 - DOI - PMC - PubMed
    1. BiCARB Study Group. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Med. 2020;18(1):91. doi:10.1186/s12916-020-01542-9 - DOI - PMC - PubMed
    1. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86(5):1031–1038. doi:10.1038/ki.2014.83 - DOI - PubMed
    1. Wesson DE, Mathur V, Tangri N, et al. . Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet. 2019;394(10196):396–406. doi:10.1016/S0140-6736(19)31388-1 - DOI - PubMed

Publication types

MeSH terms